Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06193980
Other study ID # HS25592
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 15, 2023
Est. completion date July 2025

Study information

Verified date January 2024
Source University of Manitoba
Contact Asher Mendelson, MD PhD
Phone 204-787-1634
Email Asher.Mendelson@umanitoba.ca
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to investigate how sepsis and shock can impair microcirculation in intensive care unit (ICU) patients, which can lead to long-lasting muscle weakness/dysfunction or ICU-Acquired Weakness (ICU-AW) and exercise limitations.


Description:

This longitudinal study will assess microvascular function through four (4) follow-ups after ICU discharge: at (i) 7 days, (ii) 3 months, (iii) 6 months, and (iv) 12 months. The goal is to understand how microvascular dysfunction contributes to ICU-AW and long-term exercise limitation in ICU survivors. Specific goals are: 1. Characterize the natural trajectory of skeletal muscle microvascular function in ICU survivors using high-resolution NIRS. 2. Demonstrate an impairment in skeletal muscle microvascular oxygen delivery and cardiovascular blood flow regulation in ICU survivors.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date July 2025
Est. primary completion date July 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients who have received mechanical ventilation for at least 7 days in the MICU or SICU and have subsequently been discharged. - Patients enrolled in existing microvascular monitoring study in the ICU regardless of duration of mechanical ventilation. Exclusion Criteria: - Unable to provide consent - Trajectory of health expected to be significantly limited in the upcoming 12 months

Study Design


Locations

Country Name City State
Canada Health Sciences Centre Winnipeg Winnipeg Manitoba

Sponsors (1)

Lead Sponsor Collaborator
University of Manitoba

Country where clinical trial is conducted

Canada, 

References & Publications (2)

Heyland DK, Garland A, Bagshaw SM, Cook D, Rockwood K, Stelfox HT, Dodek P, Fowler RA, Turgeon AF, Burns K, Muscedere J, Kutsogiannis J, Albert M, Mehta S, Jiang X, Day AG. Recovery after critical illness in patients aged 80 years or older: a multi-center prospective observational cohort study. Intensive Care Med. 2015 Nov;41(11):1911-20. doi: 10.1007/s00134-015-4028-2. Epub 2015 Aug 26. — View Citation

Muscedere J, Bagshaw SM, Boyd G, Sibley S, Norman P, Day A, Hunt M, Rolfson D. The frailty, outcomes, recovery and care steps of critically ill patients (FORECAST) study: pilot study results. Intensive Care Med Exp. 2022 Jun 10;10(1):23. doi: 10.1186/s40635-022-00446-7. Erratum In: Intensive Care Med Exp. 2023 Jan 5;11(1):1. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Microvascular Hemoglobin Content Microvascular regulation of blood flow distribution will be analyzed with near-infrared spectroscopy (NIRS) device by showing time-dependent changes Total hemoglobin (THb) on the brachioradialis muscle to characterize microvascular function. This will be recorded at rest for 20 minutes. Tests will be conducted on up to four (4) different occasions after ICU discharge: (i) 7 days, (ii) 3 months, (iii) 6 months, and (iv) 12 months.
Primary Vascular Occlusion Test Blood pressure cuff will be inflated to 180 mmHg or 30 mmHg above systolic blood pressure (whichever is higher) and kept occluded for 3 minutes, followed by release and continued monitoring for 5 minutes. NIRS is simultaneously applied to the brachioradialis and change in tissue saturation index is measured throughout the test. Tests will be conducted on up to four (4) different occasions after ICU discharge: (i) 7 days, (ii) 3 months, (iii) 6 months, and (iv) 12 months.
Primary VO2 peak oxygen uptake Peak Oxygen uptake (VO2, mL/kg/min) will be measured during incremental exercise on a cycle ergometer during cardiopulmonary exercise testing (CPET) Tests will be conducted on up to three (3) different occasions after ICU discharge: (i) 3 months, (ii) 6 months, and (iii) 12 months.
Primary oxygen on/off kinetics time constant (seconds) of oxygen uptake will be assessed at the transition to constant work rate exercise at the beginning of CPET; time constant (seconds) of oxygen uptake will also be assessed at the transition to rest at the end of CPET after reaching VO2 peak Tests will be conducted on up to three (3) different occasions after ICU discharge: (i) 3 months, (ii) 6 months, and (iii) 12 months.
Primary Anaerobic threshold Work rate at anaerobic threshold (AT), represented at percentage of VO2 peak will be quantified with CPET. This corresponds to the time where oxygen (O2) utilization and carbon dioxide (CO2) production curves begin to diverge. Tests will be conducted on up to three (3) different occasions after ICU discharge: (i) 3 months, (ii) 6 months, and (iii) 12 months.
Primary Medical Research Council (MRC) sum score Medical Research Council (MRC) sum score tests power in muscle groups for upper and lower extremities and score is tallied as the sum of all tested muscles. Value ranges from complete paralysis (0/60) to full strength (60/60). Score less than 48/60 denotes clinically significant weakness Tests will be conducted on up to three (3) different occasions after ICU discharge: (i) 3 months, (ii) 6 months, and (iii) 12 months.
Primary NIRS deoxygenation during exercise (deoxy-hemoglobin) NIRS will be applied to the vastus lateralis during exercise testing. Deoxygenation profile, as measured by increase in deoxy-hemoglobin will be recorded throughout exercise. Higher values indicate impaired oxygen delivery to tissue. Tests will be conducted on up to three (3) different occasions after ICU discharge: (i) 3 months, (ii) 6 months, and (iii) 12 months.
Primary NIRS deoxygenation during exercise (tissue saturation index) NIRS will be applied to the vastus lateralis during exercise testing. Deoxygenation profile, as measured by decrease in tissue saturation index will be recorded throughout exercise. Lower values indicate impaired oxygen delivery to tissue. Tests will be conducted on up to three (3) different occasions after ICU discharge: (i) 3 months, (ii) 6 months, and (iii) 12 months.
Primary 6-minute walk distance distance (meters) walked in 6 minutes will be evaluated as a general marker of fitness, in accordance with standard American Thoracic Society (ATS) guidelines Tests will be conducted on up to three (3) different occasions after ICU discharge: (i) 3 months, (ii) 6 months, and (iii) 12 months.
Primary Forced Expiratory Volume at 1-second (FEV1) Standard spirometry techniques are used to quantify the volume of expired breath (Litres) in 1 second, and represented as a %predicted compared to reference values. All tests are performed in accordance with standard ATS guidelines Tests will be conducted on up to three (3) different occasions after ICU discharge: (i) 3 months, (ii) 6 months, and (iii) 12 months.
Primary Forced Vital Capacity (FVC) Standard spirometry techniques are used to quantify the maximum volume of expired breath (Litres), and represented as a %predicted compared to reference values. All tests are performed in accordance with standard ATS guidelines Tests will be conducted on up to three (3) different occasions after ICU discharge: (i) 3 months, (ii) 6 months, and (iii) 12 months.
Secondary Functional Independence Measure (FIM) Questionnaire will assess functional capacity, and will be administered by research staff. Response will be sought directly from the patient. FIM is scored with motor (13-91) and cognitive (5-35). Lower scores indicate lower functional independence Questionnaire will be conducted on up to four (4) different occasions after ICU discharge: (i) 7 days, (ii) 3 months, (iii) 6 months, and (iv) 12 months.
Secondary Frailty Index The frailty index identifies 42 deficits, each coded as 0 (absent), 1 (present), or 0.5 (where intermediate values were possible). It was calculated as the cumulative proportion of deficits present (minimum score 0; maximum score 1.0), and then graded as mild (0 and 0.2), moderate (0.2 and 0.4) or severe frailty (>0.4). See references for studies where Index is derived. Questionnaire will be conducted on up to three (3) different occasions after ICU discharge: (i) 3 months, (ii) 6 months, and (iii) 12 months.
Secondary Postural Transitions Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) will be recorded continuously during postural transitions (lie to stand; sit to stand) to evaluate cardiovascular blood flow regulation Tests will be conducted on up to three (3) different occasions after ICU discharge: (i) 3 months, (ii) 6 months, and (iii) 12 months.
Secondary Recruitment and retention The number of completed sessions within 12 months for each eligible patient will be recorded. Ongoing throughout 12 months after ICU discharge
Secondary NIRS deoxygenation during handgrip (deoxy-hemoglobin) NIRS will be applied to the brachioradialis during handgrip. Deoxygenation profile, as measured by increase in deoxy-hemoglobin, will be recorded throughout incremental increases in handgrip intensity. Tests will be conducted on up to four (4) different occasions after ICU discharge: (i) 7 days, (ii) 3 months, (iii) 6 months, and (iv) 12 months.
Secondary NIRS deoxygenation during handgrip (tissue saturation index) NIRS will be applied to the brachioradialis during handgrip. Deoxygenation profile, as measured by decrease in tissue saturation index, will be recorded throughout incremental increases in handgrip intensity. Tests will be conducted on up to four (4) different occasions after ICU discharge: (i) 7 days, (ii) 3 months, (iii) 6 months, and (iv) 12 months.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3